<DOC>
	<DOCNO>NCT00216073</DOCNO>
	<brief_summary>In vitro data suggest synergy oxaliplatin 5-FU . The combination oxaliplatin 5-fluorouracil produce objective response rate range 27-34 % two study patient prior chemotherapy . Capecitabine design orally administer , tumor selective fluoropyrimidine , preferentially convert 5-FU tumor site high level pyrimidine nucleoside phosphorylase ( PyNPase ) tumor tissue compare normal tissue . The end result high concentration 5-fluorouracil tumor relative surround normal tissue . Trastuzumab synergistic vitro multiple chemotherapeutic agent include platinum compound . Studies show efficacy trastuzumab combine chemotherapy patient HER2 overexpressing metastatic breast cancer . This trial investigate activity capecitabine oxaliplatin administer trastuzumab ( CAPOX-T ) patient HER2 overexpressing patient advanced disease .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin Trastuzumab Treating Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - CAPOX-T ( 21 day cycle ) : Capecitabine 825 mg/m2 orally twice daily Days 1-14Oxaliplatin 100 mg/m2 intravenously Day 1 - Trastuzumab : 6 mg/kg intravenously Day 1.8mg/kg load dose give cycle 1 patient without previous trastuzumab therapy . Patients may continue combination therapy progression toxicity intervenes . Patients discontinue either cytotoxic agent due toxicity may , investigator discretion , continue therapy remain agent study progressive disease ECOG performance status 0 1 Hematopoietic : · - ANC &gt; 1,200/mm3· - Platelets &gt; 100,000/mm3 Hepatic : · - Total bilirubin &lt; 1.5 x ULN· - AST &lt; 2 x ULN ( 5 x ULN patient know liver involvement ) Renal : · - Serum creatinine &lt; 1.5 x ULN estimate creatinine clearance &gt; 50ml/min calculated Cockroft-Gault equation Cardiovascular : · - No clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 months.· - LVEF &gt; LLN MUGA ECHO</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologic cytologic diagnosis breast cancer evidence ( 1 ) unresectable , locally recurrent , ( 2 ) metastatic disease.· HER2 gene amplification FISH . HER protein overexpression immunohistochemistry sufficient entry.· At least one measurable lesion define RECIST . Prior hormonal therapy metastatic disease allow . Maximum one prior chemotherapy regimen trastuzumabcontaining regimen unresectable , locally recurrent metastatic disease Prior radiation therapy allow long irradiated area source measurable disease . No prior therapy capecitabine oxaliplatin set No prior therapy platinum compounds· No form cancer therapy include radiation , chemotherapy hormonal therapy within 21 day prior begin protocol therapy.· No prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil.· No prior fluoropyrimidine therapy metastatic disease allow . Prior adjuvant fluoropyrimidine therapy allow complete &gt; 12 month study entry.· No symptomatic brain metastasis . · No evidence serious concomitant systemic disorder incompatible study · No peripheral neuropathy · No major surgery within 28 day prior begin protocol therapy.· Negative pregnancy test· No current breastfeeding· No malabsorption syndrome· No evidence serious concomitant systemic disorder incompatible study· Patients must treat follow protocol therapy within 28 day prior begin protocol therapy : sorivudine , brivudine , cimetidine , allopurinol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>